Novotech Partners with Wonju Severance Christian Hospital to Drive Clinical Research Excellence in Korea
18.2.2025 14:05:00 CET | Business Wire | Press release
Novotech, a global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics at every phase, has signed a Memorandum of Understanding (MOU) with Wonju Severance Christian Hospital. The partnership between Wonju Severance Christian Hospital, located in Gangwon province of South Korea and Novotech marks the beginning of a new strategic collaboration focused on enhancing clinical research and medical innovation.
The partnership brings together Novotech’s global expertise in clinical trial management and Wonju Severance Christian Hospital’s outstanding research capabilities. The two organizations aim to enhance the quality of clinical trials and contributing to the development of cutting-edge therapeutics and improving patient care in the region.
At the signing ceremony, Prof. Young Uh, President of Wonju Severance Christian Hospital, emphasized the importance of the partnership, stating, “I am pleased to establish our first official partnership agreement with a globally reputable CRO like Novotech. Our hospital, the largest hospital-beds in the Gangwon region of South Korea provides great infrastructure of medical care, attracting patients from across the region. We are excited to work together with Novotech to further elevate our research and clinical services.” said Prof. Uh.
Dr. Yooni Kim, Managing Director Asia-Pacific at Novotech, highlighted the importance of strong collaboration in clinical research. “Collaboration with outstanding investigators is vital to the success of clinical trials. We look forward to working with the talented research team at Wonju Severance Christian Hospital to drive global clinical trials. We also hope this partnership will help extend clinical trial opportunities to a good-quality hospital beyond Seoul to other regions, contributing positively to local communities for patients.”
Through the strategic alliance, Novotech and Wonju Severance Christian Hospital aim to set new leverage their combined expertise to set new standards in clinical trials and medical services. The partnership will foster innovation and support Korea’s aspiration to lead the globalization of its medical industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218415353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 13:00:00 CEST | Press release
The Cognition Index Research Report, launched in partnership with Philip Morris International, warns of “Cognitive Atrophy” and a growing AI trust gap in the workplace Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says M
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit
Compass Pathways to Participate in Investor Conferences the Week of September 14th10.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 11:00:00 CEST | Press release
Independent LNG infrastructure and technology company expands investment in proprietary technology, modular solutions and global project development. GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence acro
EUMETSAT Takes Control of MTG-I210.9.2026 09:30:00 CEST | Press release
EUMETSAT’s Mission Control Centre in Darmstadt, Germany, took over control of the newest addition to its fleet of meteorological satellites, Meteosat Third Generation Imager 2 (MTG-I2), on 9 September 2026, following the successful completion of its Launch and Early Orbit Phase (LEOP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909889951/en/ MTG-I2 in orbit MTG-I2 launched from Europe’s Spaceport in French Guiana on 27 August 2026 and has now reached its geostationary orbit, around 36,000 km above Earth. During LEOP, carried out for EUMETSAT by Telespazio, communications with the satellite were established, its solar arrays deployed and a series of precise manoeuvres brought it to its designated orbital position. The spacecraft has now been handed over to EUMETSAT’s flight operations teams. EUMETSAT, working with ESA and European industry, will now begin extensive calibration and validation activities to prepare the s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom